Rhinomed Limited

ASX:RNO Stock Report

Market Cap: AU$11.5m

Rhinomed Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Michael Johnson

Chief executive officer

AU$531.6k

Total compensation

CEO salary percentage69.8%
CEO tenure11yrs
CEO ownership0.6%
Management average tenureno data
Board average tenure5.5yrs

Recent management updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10
Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10
Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Is Rhinomed (ASX:RNO) Using Too Much Debt?

Mar 03
Is Rhinomed (ASX:RNO) Using Too Much Debt?

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Mar 01
Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Jul 09
Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

Mar 01
Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Jan 25
Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Dec 20
How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

CEO Compensation Analysis

How has Michael Johnson's remuneration changed compared to Rhinomed's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023AU$532kAU$371k

-AU$11m

Mar 31 2023n/an/a

-AU$9m

Dec 31 2022n/an/a

-AU$7m

Sep 30 2022n/an/a

-AU$6m

Jun 30 2022AU$369kAU$301k

-AU$5m

Mar 31 2022n/an/a

-AU$6m

Dec 31 2021n/an/a

-AU$6m

Sep 30 2021n/an/a

-AU$8m

Jun 30 2021AU$2mAU$304k

-AU$9m

Mar 31 2021n/an/a

-AU$8m

Dec 31 2020n/an/a

-AU$7m

Sep 30 2020n/an/a

-AU$7m

Jun 30 2020AU$1mAU$304k

-AU$7m

Mar 31 2020n/an/a

-AU$8m

Dec 31 2019n/an/a

-AU$8m

Sep 30 2019n/an/a

-AU$7m

Jun 30 2019AU$748kAU$305k

-AU$6m

Mar 31 2019n/an/a

-AU$5m

Dec 31 2018n/an/a

-AU$5m

Sep 30 2018n/an/a

-AU$5m

Jun 30 2018AU$363kAU$255k

-AU$4m

Mar 31 2018n/an/a

-AU$4m

Dec 31 2017n/an/a

-AU$5m

Sep 30 2017n/an/a

-AU$5m

Jun 30 2017AU$672kAU$231k

-AU$4m

Compensation vs Market: Michael's total compensation ($USD347.11K) is about average for companies of similar size in the Australian market ($USD300.74K).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Johnson

11yrs

Tenure

AU$531,600

Compensation

Mr. Michael Johnson serves as the Chief Executive Officer, Managing Director and Executive Director of Rhinomed Limited (formerly, Consegna Group Limited) since February 1, 2013. Mr. Johnson serves as a Di...

Board Members

NamePositionTenureCompensationOwnership
Michael Johnson
CEO, MD & Executive Director11yrsAU$531.60k0.64%
A$ 73.9k
Ross MacDonald
Member of the Medical Advisory Boardno datano datano data
Ronald Dewhurst
Independent Non-Executive Chairman8.2yrsAU$110.00k6.88%
A$ 792.3k
Steve Harris
Member of the Medical Advisory Boardno datano datano data
Lynette Swinburne
Non-Executive Director1.4yrsAU$58.45k0.062%
A$ 7.1k
John McBain
Non-Executive Director2.8yrsAU$73.33k18.43%
A$ 2.1m

5.5yrs

Average Tenure

Experienced Board: RNO's board of directors are considered experienced (5.5 years average tenure).